Skip to main content
OpenTrials
Completed

NCT Number: NCT05880693

Comparisons Between Dexmedetomidine and Magnesium Sulfate in Controlled Hypotension During Rhinoplasty Surgeries

General anesthesia organizes the best option for controlled blood pressure during rhinoplasty surgery. The primary agent applied in controlling hypotension should have particular unique characteristics. The dexmedetomidine central and peripheral sympatholytic performance is usually indicated by low blood pressure and low heart rate. magnesium sulfate is among the best agents used.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypotension Cardiovascular Diseases Vascular Diseases

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Mohamed gawad Abdel aboelsuod

Cairo, Egypt

About this study

This is a prospective comparative randomized study. 56 patients got enrolled and then divided into two groups. Group 1 received dexmedetomidine (n=28), while the group 2 received magnesium sulfate (n=28). MAP, as well as heart rate, were recorded. Surgeon satisfaction was approximated for the surgical field quality. The amount of blood loss during the entire process was measured. The score of pain was evaluated using the NRS rating scale. Sedation score through Ramsey sedation score. The time required for the first requirement of analgesia was also recorded as well as intraoperative and postoperative problems.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18-60 years old
  • ASA (American Society of Anesthesiologists) grading I and II
  • patients undergo rhinoplasty surgery under general anesthesia

Exclusion criteria

  • The pregnant ladies
  • patients suffering from hypertension ischemic heart diseases renal insufficiency, neuromuscular diseases, hepatic impairment
  • cerebrovascular inadequacy and diabetic neuropathy, coagulopathies,
  • patients taking antiplatelets
  • Refused study,
  • patients of age < 18 or > 60 were unauthorized from the study.

Treatment and study plan

Dexmedetomidine

Drug

Group 1 received dexmedetomidine

Other names: magnesium sulfate

Magnesium sulfate

Drug

the group 2 received magnesium sulfate

Primary outcomes

  1. The primary outcome was to determine the bleeding score

    Time frame: 24 hours postoperative period

    The primary outcome was to determine the bleeding score, the secondary outcomes included the mean arterial pressure as well as heart rate aiming to arrive at a surgical field free from the blood through controlled Hypotension, determination of surgeon satisfaction, and operation time, they also aided in anesthesia recovery through the use of the Aldrete score, Ramsey sedation score, and the first analgesia postoperative requirement.

Sponsors and collaborators

Lead sponsor

mohamed

Other

Collaborators

  • Al-Azhar University

Registry information

Official study title

Dexmedetomidine Versus Magnesium Sulfate in Controlled Hypotension During Rhinoplasty Surgeries

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
May 30, 2023
Registry last updated
May 31, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.